p53 expression in two cases of spiradenocarcinomas

American Journal of Dermatopathology

Volumn 22, Issue 2, 2000, Pages 104-107

  Fernandez Acenero M J ^a,b   Manzarbeitia, F ^a   Mestre, M J ^a   Requena, L ^a  

^a Fund Jiménez Díaz   (Spain)

^b NONE   (Spain)

Author keywords

Adnexal tumors; Malignant spiradenoma; Malignant transformation Spiradenoma; P53; Prognostic factors

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ARTICLE; DISEASE ASSOCIATION; HIDRADENOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SPIRADENOCARCINOMA; SWEAT GLAND CARCINOMA; TISSUE DISTRIBUTION;

ADENOCARCINOMA; ADENOMA, SWEAT GLAND; AGED; AGED, 80 AND OVER; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; NEOPLASMS, MULTIPLE PRIMARY; SWEAT GLAND NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0343674486     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000372-200004000-00003     Document Type: Article

References (15)

1. Benchimol S, Lamb P, Crawford LV, et al. Transformation associated p53 protein is encoded by a gene on human chromosome 17. Somat Cell Mol Genet 1985;11:505-9.
2. Lane DP, Benchimol S. P53: oncogene or antioncogene? Genes Dev 1990;4:1-8.
3. Wu X, Boyle JH, Olson DC, Levine AJ. The p53-mdm2 autoregulatory feed-back loop. Genes Dev 1993;7:1126-32.
4. Isola J, Visakorpi T, Holli K. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-17.
5. Goh HS, Yao J, Smith DR. P53 point mutations and survival in colorectal cancer patients. Cancer Res 1995;55:5271-21.
6. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma. An immunohistochemical study of epidemiologic risk factors, histologic features and prognosis. J Clin Oncol 1995;13:821-30.
7. Petty RD, Cree IA, Sutherland LA, et al. Expression of the p53 tumor suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun 1994;199:264-70.
8. Vogt T, Zipperer KH, Vogt A, Holzel D, Landthaler M, Stolz W. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology 1997;30:57-63.
9. Healy E, Angus B, Lawrence CM, Rees JL. Prognostic value of Ki67 antigen expression in basal cell carcinomas. Br J Dermatol 1995;133:737-41.
10. Biernat W, Kordek R, Wozniak L. Over-expression of p53 protein as an indicator of the malignant transformation in spiradenoma. Histopathology 1995;26:439-43.
11. Biernat W, Peraud A, Wozniak L, Ohgaki H. p53 mutations in sweat gland carcinomas. Int J Cancer 1998;76:317-20.
12. Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma PD. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers and clinical stage in human breast cancer. Am J Clin Pathol 1992;98:408-18.
13. Stenback F, Makinen M, Jussila T. p53 expression in skin carcinogenesis and its relationship to cell proliferation and tumor growth. Eur J Cancer 1998;34:1415-24.
14. Tav JS, Tapen EM, Solari PG. Malignant eccrine spiradenoma: case report and literature review. Am J Clin Oncol 1997;20:552-7.
15. Saboorian MH, Kenny M, Ashfaq R, Albores-Saavedra J. Carcinosarcoma arising in eccrine spiradenoma of the breast: report of a case and review of the literature. Arch Pathol Lab Med 1996; 120:501-4.